Based on evidence the company submitted on the test, and helped by its low pricing, Color also has preferred provider status with a number of plans.
The company, which has been offering its hereditary cancer risk test at a self-pay rate of around $250, will continue to work with insurers to grow in-network status.
With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
Any short-term gains the bill may have on encouraging healthier lifestyles wouldn’t be worth the crippling effects it could have on the genomics field, leaders in the space said.
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The database is intended to provide the research community with a resource of control cases to aid in the evaluation of variants of unknown significance in breast cancer.
Under the Color Family Testing Program, family members of patients who tested positive for a gene on Color's hereditary cancer test can be tested for $50.
A year after launching the test in the US, the company is making it available in more than 100 countries, partnering with distributors in Israel, Turkey, and Finland.
Under the terms of the deal, Color Genomics will integrate Kapa Biosystems' library construction reagents into its NGS workflow.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.